Jul 09, 2024
Mitsubishi Tanabe Pharma America to Feature RADICAVA ORS® (edaravone) Real-World Data at 2024 ALS Nexus Conference
Jun 28, 2024
Mitsubishi Tanabe Pharma America to Present Latest Parkinson's Disease Research at the 10th Congress of the European Academy of Neurology
Mar 01, 2024
Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference
Jun 10, 2020
Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories
Jun 01, 2020
Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta
May 20, 2020
Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers
May 05, 2020
Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)
Apr 29, 2020
Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec
Dec 04, 2019
Mitsubishi Tanabe Pharma America to Present Real-World Data on RADICAVA® (edaravone) for ALS at the 30th International Symposium on ALS/MND
Nov 25, 2019
Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS
Nov 05, 2019
Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (Edaravone) for Amyotrophic Lateral Sclerosis
Sep 20, 2019
Mitsubishi Tanabe Pharma America To Present On ALS Clinical Programs At 2019 Muscle Study Group Annual Scientific Meeting
Aug 08, 2019
More Than 4,000 U.S. Patients With ALS Treated With RADICAVA® (edaravone) In Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports
May 03, 2019
Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America
Apr 11, 2019
Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference
Feb 06, 2019
Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients In The U.S. Have Been Treated With RADICAVA® (edaravone)
Nov 28, 2018
Mitsubishi Tanabe Pharma America To Showcase ALS Research At 29th International Symposium On ALS/MND In Glasgow
Nov 15, 2018
Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND
Oct 04, 2018
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of Radicava(TM) (Edaravone) to Treat ALS
Sep 24, 2018
Mitsubishi Tanabe Pharma America Appoints Joseph Scalia as Vice President of Sales and Marketing